A first-generation type I inhibitor, active on both FLT3-ITD and TKD mutants, Midostaurin proved to be efficacious in improving the survival rate of FLT3-mutated AML patients, if added to standard chemotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.